Skip to main content

Huntington’s Disease Treatment Market Size to Hit USD 2,932.2 Million By 2030, at a CAGR of 17.5%

According to Fortune Business Insights, The Huntington’s Disease Treatment Market size is anticipated to reach USD 2,932.2 Million By 2030, the market size was USD 848.0 Million in 2022 and is anticipated to rise at a CAGR of 17.5%.

Pune, India, Feb. 13, 2023 (GLOBE NEWSWIRE) — The global Huntington’s disease treatment market size reached USD 848.0 million in 2022. The market value is anticipated to increase from USD 945.8 million in 2023 to USD 2,932.2 million by 2030, recording a CAGR of 17.5% during the forecast period. Fortune Business Insights™ presents this information in a report titled, “Huntington’s Disease Treatment Market, 2023-2030.”

Huntington’s Disease (HD) is a rare degenerative, progressive disorder that affects the brain over time. It affects the patient both mentally and physically. Mental or behavioral symptoms include anxiety, depression, apathy, irritability, psychosis, and OCD. On the other hand, physical symptoms include jerky movements in fingers, hands, and face, known as chorea. Currently, there are only two clinically approved drugs for the treatment of chorea associated with HD – Tetrabenazine and Deutetrabenazine. These drugs can help alleviate chorea, which has the tendency to get worse if not addressed.

Key Industry Development:

May 2022: Neurocrine Biosciences, Inc. received the U.S. FDA’s Orphan Drug Designation for Valbenazine as a treatment for HD-associated chorea.

Request a Sample Copy of the Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/huntington-s-disease-treatment-market-107140


Report Scope & Segmentation

Report Coverage Details
Forecast Period 2023 to 2030
Forecast Period 2023 to 2030 CAGR 17.5%
2030 Value Projection USD 2,932.2 Million
Base Year 2022
Huntington’s Disease Treatment Market Size in 2022 USD 848.0 Million
Historical Data for 2019 to 2021
No. of Pages 124

Key Takeaways

  • Increasing prevalence of this disease in different regions is a key factor driving the market growth.
  • Market Growth with Early Diagnosis and Timely Treatment of disease of patients.
  • Tetrabenazine segment dominated the global market for drugs for the treatment of Huntington’s disease in 2022.
  • The North American Huntington’s disease treatment of patients market in 2022 was estimated at $787.3 million.

Browse Complete Report Details: https://www.fortunebusinessinsights.com/huntington-s-disease-treatment-market-107140


Drivers and Restraints:

Need for Advanced HD Therapeutics to Accelerate Growth in Future

The rising prevalence of HD, especially across the U.S. and several European countries, is driving the need for effective solutions for Huntington’s disease treatment. According to the Huntington’s Disease Society of America (HDSA), there were approximately 41,000 symptomatic Americans in 2021, with over 200,000 individuals at risk of inheriting the disease. The widespread prevalence of HD indicates increased demand for effective therapeutic solutions to alleviate associated symptoms.

On the contrary, strict regulatory hurdles could slow down market prospects during the forecast period.

Segments:

Tetrabenazine to Experience Monumental Demand through 2030

Based on drug, the market is segmented into deutetrabenazine, tetrabenazine, and others. The tetrabenazine segment held maximum market share in 2022 and is anticipated to experience robust demand through 2030. Availability of generic version of the drug makes it highly sought-after.

Hospital Pharmacies to Witness Growing Sales of HD Therapeutics

In terms of distribution channel, the market is divided into drug stores & retail pharmacies, hospital pharmacies, and online pharmacies. Among these, hospital pharmacies segment is expected to capture the largest Huntington’s disease treatment market share in the coming years owing to easy availability.

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/huntington-s-disease-treatment-market-107140


Report Coverage:

The report offers:

  • Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
  • Comprehensive insights into the regional developments.
  • List of major industry players.
  • Key strategies adopted by the market players.
  • Recent industry developments include product launches, partnerships, mergers, and acquisitions. 

Regional Insights:

North America to Hold Maximum Share throughout the Forecast Period

North America is anticipated to capture a substantial share of the market over the forthcoming years. The Huntington’s disease treatment market growth in this region is largely driven by increased awareness among the general public about the disease as well as the importance of its treatment. Growing support from private and public organizations through research grants will foster the regional outlook.

Meanwhile, the Europe market will grow on account of growing government initiatives to improve the quality of life for HD patients.

Competitive Landscape:

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolio.

List of Key Players Mentioned in the Report:

  • Teva Pharmaceutical Industries Ltd. (Israel)
  • H. Lundbeck A/S (Denmark)
  • Bausch Health Companies Inc. (Canada)
  • Neurocrine Biosciences, Inc. (U.S.)
  • Prilenia Therapeutics (Israel)
  • Novartis AG (Switzerland)
  • Lupin (India)
  • Hikma Pharmaceuticals PLC (U.K.)
  • Dr. Reddy’s Laboratories Ltd. (India)
  • Sun Pharmaceutical Industries, Inc. (India)

Get A Quote: https://www.fortunebusinessinsights.com/enquiry/get-a-quote/huntington-s-disease-treatment-market-107140


Major Table of Contents:

  • Global Huntington’s Disease Treatment Market Analysis, Insights and Forecast, 2019-2030
    • Market Analysis, Insights and Forecast – By Drug
      • Tetrabenazine
      • Deutetrabenazine
      • Others
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospital Pharmacies
      • Drug Stores & Retail Pharmacies
      • Online Pharmacies
    • Market Analysis, Insights and Forecast – By Region
      • North America
      • Europe
      • Asia Pacific
      • Rest of the World
  • North America Huntington’s Disease Treatment Market Analysis, Insights and Forecast, 2019-2030
    • Market Analysis, Insights and Forecast – By Drug
      • Tetrabenazine
      • Deutetrabenazine
      • Others
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospital Pharmacies
      • Drug Stores & Retail Pharmacies
      • Online Pharmacies
    • Market Analysis, Insights and Forecast – By Country
      • U.S.
      • Canada
  • Europe Huntington’s Disease Treatment Market Analysis, Insights and Forecast, 2019-2030
    • Market Analysis, Insights and Forecast – By Drug
      • Tetrabenazine
      • Deutetrabenazine
      • Others
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospital Pharmacies
      • Drug Stores & Retail Pharmacies
      • Online Pharmacies
    • Market Analysis, Insights and Forecast – By Country/Sub-Region
      • U.K.
      • Germany
      • France
      • Spain
      • Italy
      • Rest of Europe
  • Asia Pacific Huntington’s Disease Treatment Market Analysis, Insights and Forecast, 2019-2030
    • Market Analysis, Insights and Forecast – By Drug
      • Tetrabenazine
      • Deutetrabenazine
      • Others
    • Market Analysis, Insights and Forecast – By Distribution Channel
      • Hospital Pharmacies
      • Drug Stores & Retail Pharmacies
      • Online Pharmacies
    • Market Analysis, Insights and Forecast – By Country/Sub-Region
      • Japan
      • China
      • India
      • Australia
      • Rest of Asia Pacific

TOC Continued…!


Related Reports:

Neurodegenerative Diseases Drugs Market Size, Share, Revenue Forecast and Opportunities

Central Nervous System Treatment Market Size, Share, Revenue Forecast and Opportunities

Orphan Drugs Market Size, Share, Opportunities & Analysis

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.